Phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patients with muscle invasive bladder cancer ineligible or who refuse cisplatin-based chemotherapy: The PRISMA-1 study.
Por:
Duran, I, Duran, MAC, Carbonero, IG, Villares, A, Sanchez-Escribano, R, Calleja, J, Sagastibelza, N, Villafruela, A, Galante, I, Dominguez, JL, Pous, AF, Servian, P, Lainez, N, Grasa, V, Anido, U, Cimadevila, A, Dominguez, M, del Muro, XG, Buisan, O and Puente, J
Publicada:
10 feb 2025
Resumen:
Filiaciones:
Hosp Univ Marques Valdecilla, Med Oncol Dept, IDIVAL, Santander, Spain
Fdn Inst Valenciano Oncol, Valencia, Spain
Univ Gen Hosp Toledo, Nucl Med Dept, Toledo, Spain
Hosp Univ Toledo, Toledo, Spain
Univ Clin Hosp Valladolid, Valladolid, Spain
Univ Hosp Donostia, Donostia San Sebastian, Spain
Hosp Donostia, Donostia San Sebastian, Spain
Hosp Clin San Carlos, Madrid, Spain
Hosp Univ Germans Trias & Pujol HUGTiP, Inst Catala Oncol, Badalona, Spain
Hosp Badalona Germans Trias & Pujol, ICO Inst Catala Oncol Badalona, Badalona, Spain
Hosp Univ Navarra, Pamplona, Spain
Univ Clin Hosp Santiago De Compostela, Med Oncol, Santiago De Compostela, Spain
Complejo Hosp Univ Santiago De Compostela SERGAS, Santiago De Compostela, Spain
Hosp Univ Marques Valdecilla, Santander, Spain
Univ Barcelona, IDIBELL Res Inst, Inst Catala Oncol, Med Oncol Dept, Barcelona, Spain
Hosp Badalona Germans Trias & Pujol, Dept Radiol, Badalona, Barcelona, Spain
Hosp Clin San Carlos, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Dept Med Oncol, Madrid 28040, Spain
|